$PTGX
Protagonist Therapeutics, Inc

2021 Q4 Form 10-K Financial Statement

#000155837022002385 Filed on February 28, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 2020 Q4
Revenue $8.617M $27.36M $5.650M
YoY Change 52.51% -4.44% 107.72%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.260M $27.20M $4.990M
YoY Change 45.49% 45.9% 21.41%
% of Gross Profit
Research & Development $38.37M $126.0M $19.49M
YoY Change 96.89% 69.12% 22.5%
% of Gross Profit
Depreciation & Amortization $235.0K $813.0K $190.0K
YoY Change 23.68% -14.24% -5.0%
% of Gross Profit
Operating Expenses $45.63M $153.2M $24.48M
YoY Change 86.41% 64.48% 22.28%
Operating Profit -$125.8M
YoY Change 95.06%
Interest Expense $122.0K $443.0K -$50.00K
YoY Change -344.0% -25.92% -107.58%
% of Operating Profit
Other Income/Expense, Net -$13.00K -$149.0K -$10.00K
YoY Change 30.0% 223.91%
Pretax Income -$36.91M -$125.6M -$18.89M
YoY Change 95.38% 93.62% 13.45%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$36.91M -$125.6M -$18.89M
YoY Change 95.38% 89.8% 7.94%
Net Earnings / Revenue -428.3% -458.94% -334.34%
Basic Earnings Per Share -$2.71
Diluted Earnings Per Share -$766.1K -$2.710M -$476.5K
COMMON SHARES
Basic Shares Outstanding 47.73M 46.32M 38.26M
Diluted Shares Outstanding 46.32M

Balance Sheet

Concept 2021 Q4 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $326.9M $326.9M $305.8M
YoY Change 6.9% 6.9% 129.92%
Cash & Equivalents $123.7M $123.7M $117.4M
Short-Term Investments $203.2M $203.2M $188.5M
Other Short-Term Assets $9.478M $8.503M $6.300M
YoY Change 50.44% 41.72% 14.55%
Inventory
Prepaid Expenses
Receivables
Other Receivables $975.0K $311.0K
Total Short-Term Assets $340.7M $340.7M $315.6M
YoY Change 7.96% 7.96% 117.19%
LONG-TERM ASSETS
Property, Plant & Equipment $1.798M $6.734M $1.462M
YoY Change 22.98% 5.22% -13.03%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $2.000M
YoY Change
Other Assets $225.0K $225.0K $500.0K
YoY Change -55.0% -55.0% -73.68%
Total Long-Term Assets $6.959M $6.959M $8.862M
YoY Change -21.47% -21.81% -7.75%
TOTAL ASSETS
Total Short-Term Assets $340.7M $340.7M $315.6M
Total Long-Term Assets $6.959M $6.959M $8.862M
Total Assets $347.7M $347.7M $324.5M
YoY Change 7.16% 7.15% 109.45%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.600M $1.600M $3.075M
YoY Change -47.97% -48.39% 10.22%
Accrued Expenses $37.72M $39.51M $18.50M
YoY Change 103.89% 98.54% 49.66%
Deferred Revenue $1.601M $14.48M
YoY Change -88.94% -18.38%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $44.02M $44.02M $40.24M
YoY Change 9.38% 9.49% 13.66%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $3.658M $3.658M $121.0K
YoY Change 2923.14% -20.48% -99.59%
Total Long-Term Liabilities $3.658M $3.658M $121.0K
YoY Change 2923.14% -20.48% -99.69%
TOTAL LIABILITIES
Total Short-Term Liabilities $44.02M $44.02M $40.24M
Total Long-Term Liabilities $3.658M $3.658M $121.0K
Total Liabilities $47.67M $47.67M $44.86M
YoY Change 6.27% 6.18% -40.15%
SHAREHOLDERS EQUITY
Retained Earnings -$409.4M -$283.8M
YoY Change 44.24% 30.39%
Common Stock $709.7M $563.4M
YoY Change 25.97% 89.15%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $300.0M $300.0M $279.6M
YoY Change
Total Liabilities & Shareholders Equity $347.7M $347.7M $324.5M
YoY Change 7.16% 7.15% 109.45%

Cashflow Statement

Concept 2021 Q4 2021 2020 Q4
OPERATING ACTIVITIES
Net Income -$36.91M -$125.6M -$18.89M
YoY Change 95.38% 89.8% 7.94%
Depreciation, Depletion And Amortization $235.0K $813.0K $190.0K
YoY Change 23.68% -14.24% -5.0%
Cash From Operating Activities -$26.94M -$107.9M -$18.86M
YoY Change 42.84% 48.81% 31.98%
INVESTING ACTIVITIES
Capital Expenditures -$196.0K $1.101M -$120.0K
YoY Change 63.33% 133.76% -45.45%
Acquisitions
YoY Change
Other Investing Activities $28.06M -$14.76M -$74.27M
YoY Change -137.79% -83.69% 502.35%
Cash From Investing Activities $27.87M -$15.86M -$74.41M
YoY Change -137.45% -82.56% 492.91%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $123.8M
YoY Change -41.95%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.173M 129.9M 127.0M
YoY Change -98.29% -47.53% 1198.36%
NET CHANGE
Cash From Operating Activities -26.94M -107.9M -18.86M
Cash From Investing Activities 27.87M -15.86M -74.41M
Cash From Financing Activities 2.173M 129.9M 127.0M
Net Change In Cash 3.101M 6.072M 33.71M
YoY Change -90.8% -92.8% -297.6%
FREE CASH FLOW
Cash From Operating Activities -$26.94M -$107.9M -$18.86M
Capital Expenditures -$196.0K $1.101M -$120.0K
Free Cash Flow -$26.74M -$109.0M -$18.74M
YoY Change 42.71% 49.36% 33.19%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2021-01-31#LicenseAndServiceMember
CY2021 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2021-01-31#LicenseAndServiceMember
CY2020Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2021Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001377121
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43745465
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
47838330
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
CY2019 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2021-01-31#LicenseAndServiceMember
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-37852
CY2021 dei Entity Registrant Name
EntityRegistrantName
PROTAGONIST THERAPEUTICS, INC.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-0505495
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
7707 Gateway Boulevard, Suite 140
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Newark
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94560
CY2021 dei City Area Code
CityAreaCode
510
CY2021 dei Local Phone Number
LocalPhoneNumber
474-0170
CY2021 dei Security12b Title
Security12bTitle
Common Stock, $0.00001 par value
CY2021 dei Trading Symbol
TradingSymbol
PTGX
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
true
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
2100000000
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
48413555
CY2021 dei Auditor Firm
AuditorFirmId
42
CY2019 dei Auditor Firm
AuditorFirmId
238
CY2021 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2021 dei Auditor Location
AuditorLocation
Redwood City, California
CY2019 dei Auditor Name
AuditorName
PricewaterhouseCoopers LLP
CY2019 dei Auditor Location
AuditorLocation
San Jose, California
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
123665000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
117358000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
203235000
CY2020Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
188451000
CY2020Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
10000
CY2021Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
1566000
CY2020Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
2426000
CY2021Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
2792000
CY2020Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
1084000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9478000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6277000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
340736000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
315606000
CY2020Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
2000000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1798000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1462000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
225000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
450000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4936000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4950000
CY2021Q4 us-gaap Assets
Assets
347695000
CY2020Q4 us-gaap Assets
Assets
324468000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1600000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3075000
CY2021Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
899000
CY2020Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
2732000
CY2021Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
37716000
CY2020Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
18498000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1601000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
14477000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2200000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1459000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
44016000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
40241000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3658000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4500000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
121000
CY2021Q4 us-gaap Liabilities
Liabilities
47674000
CY2020Q4 us-gaap Liabilities
Liabilities
44862000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
47838330
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43745465
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
709682000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
563389000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-299000
CY2021 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-182000
CY2020 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
266000
CY2019 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-44000
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-145000
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-17000
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
56000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
28000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-409362000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-283811000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
300021000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
279606000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
347695000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
324468000
CY2021 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
27357000
CY2020 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
28628000
CY2019 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
231000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
126006000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
74506000
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
65003000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
27196000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18638000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15749000
CY2021 us-gaap Operating Expenses
OperatingExpenses
153202000
CY2020 us-gaap Operating Expenses
OperatingExpenses
93144000
CY2019 us-gaap Operating Expenses
OperatingExpenses
80752000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-125845000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-64516000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-80521000
CY2021 us-gaap Investment Income Interest
InvestmentIncomeInterest
443000
CY2020 us-gaap Investment Income Interest
InvestmentIncomeInterest
900000
CY2019 us-gaap Investment Income Interest
InvestmentIncomeInterest
2813000
CY2020 us-gaap Interest Expense
InterestExpense
598000
CY2019 us-gaap Interest Expense
InterestExpense
169000
CY2020 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-585000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-149000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-46000
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-125551000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-64845000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-77878000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1305000
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-691000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-125551000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-66150000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-77187000
CY2021 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.71
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.92
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.98
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
46322910
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
34396446
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
25894024
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-125551000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-66150000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-77187000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-125878000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-65901000
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-77175000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
112515000
CY2019 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1779000
CY2021 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
-1833000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8353000
CY2019 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
12000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-77187000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
79964000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
212974000
CY2020 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2799000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7899000
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
249000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-66150000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
279606000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
123804000
CY2021 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
6283000
CY2021 ptgx Shares Withheld For Net Settlements Of Tax Withholding Upon Vesting Of Restricted Stock Units
SharesWithheldForNetSettlementsOfTaxWithholdingUponVestingOfRestrictedStockUnits
189000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
16395000
CY2021 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-327000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-125551000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
300021000
CY2021 us-gaap Profit Loss
ProfitLoss
-125551000
CY2020 us-gaap Profit Loss
ProfitLoss
-66150000
CY2019 us-gaap Profit Loss
ProfitLoss
-77187000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
16395000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
7899000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
8353000
CY2021 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1962000
CY2020 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1775000
CY2019 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1792000
CY2021 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1830000
CY2020 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-37000
CY2019 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
594000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
813000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
948000
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
732000
CY2020 us-gaap Income Tax Credits And Adjustments
IncomeTaxCreditsAndAdjustments
1438000
CY2019 us-gaap Income Tax Credits And Adjustments
IncomeTaxCreditsAndAdjustments
-775000
CY2020 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-585000
CY2019 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-8000
CY2021 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
1775000
CY2020 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
990000
CY2019 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-1411000
CY2021 us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
-860000
CY2020 us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
-4329000
CY2019 us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
2168000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3227000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1102000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2820000
CY2021 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-1390000
CY2020 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
309000
CY2019 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-3000000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
1941000
CY2020 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
1471000
CY2019 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
201000
CY2021 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
19097000
CY2020 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
5840000
CY2019 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
1098000
CY2021 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-12876000
CY2020 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-27053000
CY2019 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
33307000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
2049000
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
1885000
CY2021 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-121000
CY2020 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
121000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-107865000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-72484000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-41527000
CY2021 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
286589000
CY2020 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
280027000
CY2019 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
166936000
CY2021 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
271830000
CY2020 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
189533000
CY2019 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
114193000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1101000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
471000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
967000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-15860000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-90965000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-53710000
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
123829000
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
213303000
CY2021 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
6283000
CY2020 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
2799000
CY2019 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1779000
CY2021 ptgx Shares Withheld For Net Settlement Of Tax Withholding Upon Vesting Of Restricted Stock Units
SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnits
189000
CY2020 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
42062000
CY2019 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
34492000
CY2020 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
10524000
CY2020 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
14000
CY2019 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
9765000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
129923000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
247626000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
46036000
CY2021 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-126000
CY2020 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
175000
CY2019 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-26000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
6072000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
84352000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-49227000
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q4 ptgx Cash Cash Equivalents And Marketable Securities Carrying Value
CashCashEquivalentsAndMarketableSecuritiesCarryingValue
326900000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-409400000
CY2020 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
85000
CY2019 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
100000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
117818000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
33466000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
82693000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
123890000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
117818000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
33466000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
438000
CY2019 us-gaap Interest Paid Net
InterestPaidNet
70000
CY2021 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
143000
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, accruals for research and development activities, stock-based compensation, income taxes, marketable securities and leases. Estimates related to revenue recognition include actual costs incurred versus total estimated costs of the Company’s deliverables to determine percentage of completion in addition to the application and estimates of potential revenue constraints in the determination of the transaction price under its license and collaboration agreements. Management bases these estimates on historical and anticipated results, trends and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to forecasted amounts and future events.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Due to the ongoing COVID-19 pandemic, there has been uncertainty and disruption in the global economy and financial markets. The Company has taken into consideration any known COVID-19 impacts in its accounting estimates to date and is not aware of any additional specific events or circumstances that would require any additional updates to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of the date of issuance of this Annual Report on Form 10-K. These estimates may change as new events occur and additional information is obtained. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Actual results could differ materially from these estimates under different assumptions or conditions.</p>
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentrations of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and marketable securities. Substantially all of the Company’s cash is held by two financial institutions that </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. The primary focus of the Company’s investment strategy is to preserve capital and to meet liquidity requirements. The Company’s cash equivalents, and marketable securities are managed by external managers within the guidelines of the Company’s investment policy. The Company’s investment policy addresses the level of credit exposure by limiting concentration in any one corporate issuer and establishing a minimum allowable credit rating. To manage its credit risk exposure, the Company maintains its U.S. portfolio of cash equivalents and marketable securities in fixed income securities denominated and payable in U.S. dollars. Permissible investments of fixed income securities include obligations of the U.S. government and its agencies, money market instruments including commercial paper and negotiable certificates of deposit, and highly rated corporate debt obligations and money market funds, and highly rated supranational and sovereign government securities.</span><span style="white-space:pre-wrap;"> </span></p>
CY2021Q4 ptgx Cash Number Of Financial Institutions
CashNumberOfFinancialInstitutions
2
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
123665000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
117358000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
33006000
CY2020Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
10000
CY2019Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
10000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
225000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
450000
CY2019Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
450000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
123890000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
117818000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
33466000
CY2021 ptgx Potential Qualified Discount Federal Income Tax Credit
PotentialQualifiedDiscountFederalIncomeTaxCredit
25
CY2021 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
2800000
CY2020 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
14100000
CY2019 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
1600000
CY2021Q4 ptgx Cash Equivalents And Marketable Securities Amortized Cost
CashEquivalentsAndMarketableSecuritiesAmortizedCost
318713000
CY2021Q4 ptgx Cash Equivalents And Marketable Securities Gross Unrealized Loss
CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss
143000
CY2021Q4 ptgx Cash Equivalents And Marketable Securities Fair Value
CashEquivalentsAndMarketableSecuritiesFairValue
318570000
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
115335000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
203235000
CY2021Q4 ptgx Cash Equivalents And Marketable Securities Fair Value
CashEquivalentsAndMarketableSecuritiesFairValue
318570000
CY2020Q4 ptgx Cash Equivalents And Marketable Securities Amortized Cost
CashEquivalentsAndMarketableSecuritiesAmortizedCost
304142000
CY2020Q4 ptgx Cash Equivalents And Marketable Securities Gross Unrealized Gain
CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain
12000
CY2020Q4 ptgx Cash Equivalents And Marketable Securities Gross Unrealized Loss
CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss
10000
CY2020Q4 ptgx Cash Equivalents And Marketable Securities Fair Value
CashEquivalentsAndMarketableSecuritiesFairValue
304144000
CY2020Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
113693000
CY2020Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
188451000
CY2020Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
2000000
CY2020Q4 ptgx Cash Equivalents And Marketable Securities Fair Value
CashEquivalentsAndMarketableSecuritiesFairValue
304144000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
203200000
CY2020Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
188500000
CY2021 ptgx Current Contractual Maturities Maximum Period
CurrentContractualMaturitiesMaximumPeriod
P1Y
CY2020Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
2000000.0
CY2021 ptgx Noncurrent Contractual Maturities Minimum Period
NoncurrentContractualMaturitiesMinimumPeriod
P1Y
CY2021 ptgx Noncurrent Contractual Maturities Maximum Period
NoncurrentContractualMaturitiesMaximumPeriod
P2Y
CY2020 us-gaap Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
0
CY2021 us-gaap Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
0
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9478000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6277000
CY2021Q4 ptgx Prepaid Manufacturing Of Clinical Materials
PrepaidManufacturingOfClinicalMaterials
5242000
CY2020Q4 ptgx Prepaid Manufacturing Of Clinical Materials
PrepaidManufacturingOfClinicalMaterials
3517000
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1746000
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1440000
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1515000
CY2020Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1009000
CY2021Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
975000
CY2020Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
311000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6056000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4935000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4258000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3473000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1798000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1462000
CY2021 us-gaap Depreciation
Depreciation
813000
CY2020 us-gaap Depreciation
Depreciation
789000
CY2019 us-gaap Depreciation
Depreciation
703000
CY2021Q4 ptgx Accrued Clinical And Research Related Expenses Current
AccruedClinicalAndResearchRelatedExpensesCurrent
27950000
CY2020Q4 ptgx Accrued Clinical And Research Related Expenses Current
AccruedClinicalAndResearchRelatedExpensesCurrent
11335000
CY2021Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
7125000
CY2020Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
6413000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
734000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
668000
CY2021Q4 ptgx Accrued Milestone Payment To Former Collaboration Partner
AccruedMilestonePaymentToFormerCollaborationPartner
1500000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
407000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
82000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
37716000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18498000
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
1500000
CY2017Q1 us-gaap Security Deposit
SecurityDeposit
450000
CY2021Q1 us-gaap Security Deposit
SecurityDeposit
225000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4936000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4950000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2200000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1459000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3658000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4500000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
5858000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
5959000
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y4M24D
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y4M24D
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.104
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.110
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y7M9D
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
1962000
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
1775000
CY2019 us-gaap Operating Lease Cost
OperatingLeaseCost
1792000
CY2021 us-gaap Sublease Income
SubleaseIncome
91000
CY2020 us-gaap Sublease Income
SubleaseIncome
89000
CY2019 us-gaap Sublease Income
SubleaseIncome
64000
CY2021 us-gaap Lease Cost
LeaseCost
1871000
CY2020 us-gaap Lease Cost
LeaseCost
1686000
CY2019 us-gaap Lease Cost
LeaseCost
1728000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
2049000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
1941000
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
1885000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1373000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2660000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2744000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1160000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
6564000
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
706000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
5858000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4648120
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.87
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
40000000.0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1949940
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
29.96
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
474801
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
11.34
CY2021 us-gaap Stock Issued During Period Shares Restricted Stock Award Forfeited
StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
232719
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
17.84
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5890540
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
17.66
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y5M19D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
102700000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3224575
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
13.13
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y4M17D
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
68100000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
5890540
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
17.66
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y5M19D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
102700000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
10500000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
3000000.0
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2600000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
21.94
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.76
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.45
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
11300000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
7100000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
7300000
CY2021 ptgx Expected Volatility Calculation Percentage Of Average Volatility Expected Term Of Stock Option Grants
ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants
0.75
CY2021 ptgx Expected Volatility Calculation Percentage Of Volatility Of Stock Price Since Ipo
ExpectedVolatilityCalculationPercentageOfVolatilityOfStockPriceSinceIpo
0.25
CY2021Q1 ptgx Expected Volatility Calculation Percentage Of Average Volatility Expected Term Of Stock Option Grants
ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants
0.50
CY2021Q1 ptgx Expected Volatility Calculation Percentage Of Volatility Of Stock Price Since Ipo
ExpectedVolatilityCalculationPercentageOfVolatilityOfStockPriceSinceIpo
0.50
CY2021 ptgx Number Of Equal Installments Required For Vesting Of Restricted Stock Units
NumberOfEqualInstallmentsRequiredForVestingOfRestrictedStockUnits
4
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16395000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7899000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8353000
CY2021Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
46300000
CY2021 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y8M12D
CY2020 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-88000
CY2019 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
84000
CY2021 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.50
CY2021 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
3500
CY2021 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
300000
CY2019 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2020 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1300000
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-700000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-125797000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-71073000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-72271000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
246000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
6228000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-5607000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-125551000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-64845000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-77878000
CY2020 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
-88000
CY2019 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
84000
CY2020 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
1393000
CY2019 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
-775000
CY2020 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
1393000
CY2019 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-775000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1305000
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-691000
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.019
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.019
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.012
CY2021 ptgx Effective Income Tax Rate Reconciliation Tax Credit Research Adjustment Percent
EffectiveIncomeTaxRateReconciliationTaxCreditResearchAdjustmentPercent
0.043
CY2020 ptgx Effective Income Tax Rate Reconciliation Tax Credit Research Adjustment Percent
EffectiveIncomeTaxRateReconciliationTaxCreditResearchAdjustmentPercent
0.065
CY2019 ptgx Effective Income Tax Rate Reconciliation Tax Credit Research Adjustment Percent
EffectiveIncomeTaxRateReconciliationTaxCreditResearchAdjustmentPercent
0.043
CY2020 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.009
CY2019 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.007
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.280
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.343
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.238
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.008
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.038
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.025
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.020
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.009
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
75649000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
50272000
CY2021Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
1153000
CY2021Q4 ptgx Deferred Tax Assets Operating Lease Liability
DeferredTaxAssetsOperatingLeaseLiability
1230000
CY2020Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
1237000
CY2021Q4 ptgx Deferred Tax Assets Tax Deferred Expense Reserves And Accruals And Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther
5716000
CY2020Q4 ptgx Deferred Tax Assets Tax Deferred Expense Reserves And Accruals And Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther
5332000
CY2020Q4 ptgx Deferred Tax Assets Operating Lease Liability
DeferredTaxAssetsOperatingLeaseLiability
1252000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
21197000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-77187000
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
46322910
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
14856000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
104945000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
72949000
CY2021Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
1037000
CY2020Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
1040000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1037000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1040000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
103908000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
71909000
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
32000000.0
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
19400000
CY2019 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
18500000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
19885000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
16631000
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
9466000
CY2020 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
3799000
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
184000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
13274000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
7053000
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
6981000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
33159000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
19885000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
16631000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
33200000
CY2019Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2020Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-125551000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-66150000
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
34396446
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
25894024
CY2021 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.71
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.92
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.98
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7671110
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9170067
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6750278
CY2020Q1 ptgx Percentage Of Employee Base Impacted By Restructuring Plan
PercentageOfEmployeeBaseImpactedByRestructuringPlan
0.12
CY2020Q1 us-gaap Restructuring Charges
RestructuringCharges
300000

Files In Submission

Name View Source Status
0001558370-22-002385-index-headers.html Edgar Link pending
0001558370-22-002385-index.html Edgar Link pending
0001558370-22-002385.txt Edgar Link pending
0001558370-22-002385-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
ptgx-20211231.xsd Edgar Link pending
ptgx-20211231x10k.htm Edgar Link pending
ptgx-20211231x10k006.jpg Edgar Link pending
ptgx-20211231x10k007.jpg Edgar Link pending
ptgx-20211231x10k008.jpg Edgar Link pending
ptgx-20211231x10k009.jpg Edgar Link pending
ptgx-20211231x10k_htm.xml Edgar Link completed
ptgx-20211231xex21d1.htm Edgar Link pending
ptgx-20211231xex23d1.htm Edgar Link pending
ptgx-20211231xex23d2.htm Edgar Link pending
ptgx-20211231xex31d1.htm Edgar Link pending
ptgx-20211231xex31d2.htm Edgar Link pending
ptgx-20211231xex32d1.htm Edgar Link pending
ptgx-20211231xex4d7.htm Edgar Link pending
ptgx-20211231_cal.xml Edgar Link unprocessable
ptgx-20211231_def.xml Edgar Link unprocessable
ptgx-20211231_lab.xml Edgar Link unprocessable
ptgx-20211231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending